Company Profile
Sutro Biopharma Stock Price, News & Analysis
- Ticker:
- STRO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
24.15 USD (-3.78%)
Close
Last updated: August 6, 2026
405M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, STRO closed down 3.78% at $24.15. No new same-company headline was identified in the current news window.
Company overview
Next-Generation ADC Company
Sutro Biopharma develops site-specific and novel-format antibody-drug conjugates for cancer. Its cell-free platform enables optimization of antibodies, linkers, and payloads and supports both single-payload and dual-payload ADC designs.
Wholly Owned ADC Pipeline
STRO-004 is a Tissue Factor-targeting ADC with a DAR8 topoisomerase I payload in a first-in-human Phase 1 dose-escalation study. STRO-006 targets ITGB6, while STRO-227 is a dual-payload ADC directed against PTK7.
Portfolio and Partnership Model
Sutro advances wholly owned ADCs while using partnerships to validate and monetize its technology. Collaborations provide external funding and potential milestone or royalty economics while the company retains direct ownership of selected oncology programs.
Cell-Free Platform Differentiation
The cell-free manufacturing system allows precise placement of non-natural amino acids and controlled attachment of linker-payload combinations. This capability supports consistent site-specific ADCs and formats that are difficult to generate through conventional cell-based expression.
Partnered Platform Validation
The first dual-payload immune-stimulating ADC developed through Sutro’s collaboration with Astellas has entered clinical development and begun patient dosing, providing external validation of the company’s multi-payload design capabilities.
Future catalysts
Initial safety, pharmacokinetic, and early activity data from the Phase 1 dose-escalation study of STRO-004 were expected in mid-2026.
An IND submission for STRO-006 is planned in 2026.
An IND submission for STRO-227 is planned in 2026.
Recent news
- 01
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
Source: Sutro Biopharma
- 02
- 03
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
Source: Sutro Biopharma
- 04
Sutro Biopharma to Participate in Upcoming Investor Conferences
Source: Sutro Biopharma
- 05
Sutro Biopharma Announces Participation at the 16th World ADC London Summit
Source: Sutro Biopharma
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Sutro Biopharma (STRO)?
Sutro Biopharma (STRO) most recently closed at 24.15 USD, a -3.78% move versus the previous session.
What is the market cap of Sutro Biopharma (STRO)?
Sutro Biopharma currently has a market capitalization of 405M USD on BioPharmSignal.
What does Sutro Biopharma do?
Next-Generation ADC Company Sutro Biopharma develops site-specific and novel-format antibody-drug conjugates for cancer. Its cell-free platform enables optimization of antibodies, linkers, and payloads and supports both single-payload and dual-payload ADC designs. Wholly Owned ADC Pipeline STRO-004 is a Tissue Factor-targeting ADC with a DAR8 topoisomerase...
On which exchange is STRO stock listed?
Sutro Biopharma (STRO) is associated with NASDAQ, United States, Biopharma.
What is STRO-004?
Initial safety, pharmacokinetic, and early activity data from the Phase 1 dose-escalation study of STRO-004 were expected in mid-2026.
Which conditions is Sutro Biopharma targeting with STRO-004?
Sutro Biopharma is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Sutro Biopharma describe recent progress with STRO-004?
Initial safety, pharmacokinetic, and early activity data from the Phase 1 dose-escalation study of STRO-004 were expected in mid-2026.
What is STRO-006?
STRO-006 targets ITGB6, while STRO-227 is a dual-payload ADC directed against PTK7.